Analysts Set Nkarta, Inc. (NASDAQ:NKTX) PT at $13.25

Nkarta, Inc. (NASDAQ:NKTX) has received an average rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $13.25.

NKTX has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a report on Monday, December 29th. Wall Street Zen upgraded Nkarta from a “sell” rating to a “hold” rating in a report on Saturday, December 20th.

Nkarta Stock Down 1.3%

Shares of NKTX opened at $2.26 on Thursday. The stock has a market cap of $160.53 million, a P/E ratio of -1.64 and a beta of 0.47. The business’s 50 day moving average price is $2.26 and its 200-day moving average price is $2.10. Nkarta has a 52 week low of $1.31 and a 52 week high of $2.81.

Insider Buying and Selling

In related news, CEO Paul J. Hastings sold 26,046 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $2.07, for a total transaction of $53,915.22. Following the sale, the chief executive officer directly owned 390,023 shares of the company’s stock, valued at approximately $807,347.61. This represents a 6.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Abel Hall LLC bought a new position in shares of Nkarta in the fourth quarter worth approximately $27,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Nkarta during the fourth quarter valued at approximately $37,000. Savant Capital LLC bought a new stake in shares of Nkarta during the second quarter valued at approximately $36,000. SG Americas Securities LLC raised its holdings in Nkarta by 35.0% in the 3rd quarter. SG Americas Securities LLC now owns 23,663 shares of the company’s stock worth $49,000 after acquiring an additional 6,141 shares during the last quarter. Finally, Bailard Inc. purchased a new position in Nkarta in the 3rd quarter worth approximately $61,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.